Research services, Financial services company

Bengaluru, Oct 22 Biocon, the global biopharmaceuticals company of India, on Friday said its Q2FY22 revenue growth was up by 10 per cent at Rs 1,945 crore, primarily driven by good performance of the Research Services and Biosimilars business segments.Announcing consolidated financial results for the second quarter ending September 30, 2021, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said the factors responsible for the profit reported a growth of 17 per cent and 10 per cent respectively."EBITDA at Rs 551 crore was up by 35 per cent and PBT (before exceptional items) at Rs 276 crore went up by 27 per cent. The exceptional item relates to modification of the optionally convertible debentures of a PE investment in Biocon Biologics and reversal of SEIS claims relating to a prior period. Net Profit for Q2FY22, before such exceptional items, was Rs 188 crore, up 11 per cent. Our Core EBITDA margins for the quarter were at a healthy 33 per cent," she explained.Kiran claimed: "Biocon Biologics made strategic moves this quarter which will drive future growth of our Biosimilars business and deliver long-term value for our shareholders. The US FDA's approval of Semglee as the first interchangeable biosimilar product under the 351(k) regulatory pathway, is a historic milestone for both Biocon and Viatris, and will enable us to expand patient access to our Insulin Glargine," she said.The Executive Chairperson stated, this has led to Semglee's inclusion as a preferred Insulin Glargine brand on the National Preferred Formulary of Express Scripts, a leading Pharmacy Benefit Manager (PBM). We expect the formulary coverage to begin in January 2022 and believe Semglee has the potential to bring significant cost savings for patients, employers and PBMs," she added."The quarter also marked Biocon Biologics' strategic entry into vaccines and the infectious diseases segment through key partnerships with Serum Institute Life Sciences and Adagio Therapeutics," she underlined.Kiran said: "With the waning pandemic and improvements in supply chain conditions, I believe all three business segments, Generics, Biosimilars and Research Services, are well positioned for sustained growth in H2FY22."Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

Research ServicesFOLLOW

Research services, Latest News

Business :Mastertrust: Women Mastering Finances The Trusted Way

New Delhi, 19th August 2022: Along with ‘Azadi Ka Amrit Mahotsav’, this Independence Day is a celebration of the ... ...

Business :mastertrust: Women Mastering Finances The Trusted Way

August 18:Along with ‘Azadi Ka Amrit Mahotsav’, this Independence Day is a celebration of the Indian Investment Landscape and ... ...

Business :India targets USD 300 billion worth bioeconomy by 2030

Union Minister of State (Independent Charge) Science and Technology and Minister of State (Independent Charge) Earth Sciences Jitendra Singh said India has a target of USD 300 billion in bioeconomy by 2030. ...

International :Biocon Q3FY22 revenue at Rs 2,223 crore, up by 18%

Bengaluru, Jan 21 Biocon, a global biopharmaceuticals company, announced its consolidated financial results for the third quarter ended ... ...

International :Biocon Q2FY22 revenue up by 10% at Rs 1,945 crore

Bengaluru, Oct 22 Biocon, the global biopharmaceuticals company of India, on Friday said its Q2FY22 revenue growth was ... ...